Alamar Biosciences, Inc. · NASDAQ:ALMR
Qiming Corporate GP VI, Ltd. sold 342,626 Alamar Biosciences, Inc. shares (Form 4)
Traded Oct 21 to Oct 22, 2026 · Filed Oct 23, 2026
From Oct 21 to Oct 22, 2026, Qiming Corporate GP VI, Ltd. (10% owner) sold 342,626 Alamar Biosciences, Inc. shares at an average US$29.93 for US$10.3M, leaving 1,789,183 shares. Filed Oct 23, 2026 (Form 4).
- Sold
- 342,626 shares
- Price
- US$29.93 average (US$29.00 to US$30.81)
- Value
- US$10.3M
- Holding after
- 1,789,183 shares (held indirectly)
- Trading plan
- No
- Role
- 10% owner
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Oct 21, 2026 | Common Stock | Sale | 592 | US$29.01 | 177,734 | Indirect |
| Oct 21, 2026 | Common Stock | Sale | 677 | US$29.75 | 177,057 | Indirect |
| Oct 21, 2026 | Common Stock | Sale | 2,380 | US$30.79 | 174,677 | Indirect |
| Oct 21, 2026 | Common Stock | Sale | 22,020 | US$29.01 | 6,605,306 | Indirect |
| Oct 21, 2026 | Common Stock | Sale | 25,177 | US$29.75 | 6,580,129 | Indirect |
| Oct 21, 2026 | Common Stock | Sale | 88,434 | US$30.79 | 6,491,695 | Indirect |
| Oct 21, 2026 | Common Stock | Sale | 5,138 | US$29.01 | 1,541,222 | Indirect |
| Oct 21, 2026 | Common Stock | Sale | 5,875 | US$29.75 | 1,535,347 | Indirect |
| Oct 21, 2026 | Common Stock | Sale | 20,634 | US$30.79 | 1,514,713 | Indirect |
| Oct 21, 2026 | Common Stock | Sale | 6,151 | US$29.01 | 1,845,199 | Indirect |
| Oct 21, 2026 | Common Stock | Sale | 7,033 | US$29.75 | 1,838,166 | Indirect |
| Oct 21, 2026 | Common Stock | Sale | 24,704 | US$30.79 | 1,813,462 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 1,246 | US$29.00 | 173,431 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 994 | US$29.59 | 172,437 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 99 | US$30.81 | 172,338 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 46,290 | US$29.00 | 6,445,405 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 36,941 | US$29.59 | 6,408,464 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 3,683 | US$30.81 | 6,404,781 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 10,800 | US$29.00 | 1,503,913 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 8,620 | US$29.59 | 1,495,293 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 859 | US$30.81 | 1,494,434 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 12,931 | US$29.00 | 1,800,531 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 10,319 | US$29.59 | 1,790,212 | Indirect |
| Oct 22, 2026 | Common Stock | Sale | 1,029 | US$30.81 | 1,789,183 | Indirect |
Source
Download original · View original at SEC
Related
- Alamar Biosciences, Inc.
- Qiming Corporate GP VI, Ltd.
- Alamar Biosciences, Inc. shareholders
- Form 4 · Qiming Corporate GP VI, Ltd. · Oct 21, 2026
- Form 4 · Qiming Corporate GP VI, Ltd. · Oct 19, 2026
- Schedule 13G · Yuling Luo · Aug 13, 2026
- Schedule 13G · Qiming Corporate GP VI, Ltd. · Aug 11, 2026
- Schedule 13D/A · Sands Capital Life Sciences Pulse Fund II, L.P. · Jul 7, 2026
- Schedule 13G · Daqing Cai · Jul 2, 2026
- Schedule 13D · Nicholas Naclerio · Apr 23, 2026